NCT06061393 Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia
| NCT ID | NCT06061393 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Western Galilee Hospital-Nahariya |
| Condition | Anemia, Iron Deficiency |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-11-02 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 200 participants in total. It began in 2023-11-02 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to compare maternal outcomes such as increased hemoglobin need for blood transfusion and hemoglobin level before and post partum in women with hemoglobin \<9 gr/dl , treated with venofer and women treated with ferinject.
Eligibility Criteria
Inclusion Criteria: pregnancy\>24 weeks of gestation anemia with Hb\<9 anemia with Hb\<9.5 if symptomatic anemia or previous postpartum hemorrhage Exclusion Criteria: * Allergy to one of the study's drugs * IV iron treatment in the last month * Underlying medical conditions associated with anemia, such as thalassemia Major, renal insufficiency, or spherocytosis * Twin pregnancy * non iron deficiency anemia
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06061393 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Anemia, Iron Deficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06061393 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06061393 currently recruiting?
Yes, NCT06061393 is actively recruiting participants. Contact the research team at mayaw@gmc.gov.il for enrollment information.
Where is the NCT06061393 trial being conducted?
This trial is being conducted at Nahariya, Israel.
Who is sponsoring the NCT06061393 clinical trial?
NCT06061393 is sponsored by Western Galilee Hospital-Nahariya. The trial plans to enroll 200 participants.